Not Yet RecruitingPhase 4ACTRN12609000655246

Use of aldosterone blockade to improve cardiac function in obesity

Sponsor

The University of Queensland

Enrollment

120 participants

Start Date

Aug 15, 2009

Study Type

Interventional

Conditions

Diastolic Dysfunction

Summary

Obesity is a risk factor for the development of heart failure. Many apparently well obese subjects have cardiac dysfunction that is detectable with specialized techniques, but which may contribute to the development of heart failure. There are several potential causes for this problem, but fibrosis (scarring) of the heart may be an important one. In this study, we plan to identify whether this can be treated with the aldosterone blocker, spironolactone.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 75 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a medication that blocks the hormone aldosterone can improve heart function in people with obesity. It is for adults aged 18 to 75 with a BMI over 30. People with diabetes, heart disease, or other chronic conditions are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.